Serina Therapeutics, Inc.
SER
$1.55
-$0.08-4.91%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 100.00% | -- | 154.90% | -- | -100.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 100.00% | -- | 154.90% | -- | -100.45% |
| Cost of Revenue | 43.81% | 51.18% | 97.74% | 166.82% | 160.75% |
| Gross Profit | -42.96% | -52.06% | -95.85% | -168.03% | -209.13% |
| SG&A Expenses | 65.64% | -5.84% | 9.47% | 138.28% | 398.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.92% | 20.02% | 45.39% | 151.85% | 225.50% |
| Operating Income | -52.39% | -20.33% | -43.95% | -152.39% | -321.36% |
| Income Before Tax | -20.57% | -432.25% | -224.82% | 67.89% | -361.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.22% | -432.25% | -224.82% | 67.89% | -361.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -62.96% | -48.15% | -- | -- |
| Net Income | -21.75% | -425.18% | -223.90% | 67.95% | -360.70% |
| EBIT | -52.39% | -20.33% | -43.95% | -152.39% | -321.36% |
| EBITDA | -53.92% | -21.31% | -45.68% | -154.40% | -317.61% |
| EPS Basic | -5.22% | -384.49% | -207.36% | 90.83% | -168.99% |
| Normalized Basic EPS | -125.64% | -374.88% | -204.98% | 82.81% | -118.78% |
| EPS Diluted | -5.52% | -448.62% | -229.41% | 90.83% | -293.44% |
| Normalized Diluted EPS | -125.64% | -433.90% | -225.25% | 82.81% | -152.66% |
| Average Basic Shares Outstanding | 17.01% | 16.81% | 17.50% | 249.68% | 277.86% |
| Average Diluted Shares Outstanding | 17.01% | -3.83% | -1.51% | 249.68% | 34.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |